Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The insulin‐like growth factor (IGF) signaling pathway is involved in cell proliferation and differentiation. Elevated serum IGF1 levels have been associated with increased colorectal cancer risk; however, studies of this association with colorectal adenoma are inconclusive. We examined serum IGF1, IGF2 and IGFBP3 levels in relation to risk of advanced colorectal adenoma in a case‐control study within the prostate, lung, colorectal and ovarian cancer screening trial. A total of 764 advanced, left‐sided colorectal adenoma cases and 775 controls frequency‐matched on gender and ethnicity, without evidence of a left‐sided polyp on sigmoidoscopy were included in the current study. Serum levels of IGF1, IGF2 and IGFBP3 were measured using an enzyme linked immunosorbent assay in serum samples collected at baseline. Logistic regression was used to estimate the odds ratios (OR) and 95% confidence intervals (CI) for the associations adjusting for age, race, sex, year of blood draw, body mass index, smoking and education. Higher IGF1 levels were associated with increased adenoma risk: ORs = 1.58 (95% CI = 1.16–2.16), 1.42 (95% CI = 1.04–1.93), and 1.80 (95% CI = 1.30–2.47) for the second, third and fourth quartiles, respectively (ptrend = 0.002). Elevated IGF2 levels were also associated with increased adenoma risk (OR = 1.43, 95% CI = 1.05–1.96 for the fourth vs. first quartile, ptrend = 0.02), but the association was no longer significant after adjustment for IGF1 (ptrend = 0.28). IGFBP3 levels were not associated with adenoma risk. Our analysis showed a significant positive association between circulating IGF1 levels and risk of advanced colorectal adenoma, suggesting that IGF1 is associated with the pivotal precursor to colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“The underlying biological mechanism for involvement of the IGF signaling pathway in carcinogenesis has been reviewed by others.(1) Increased IGF1 levels are thought to increase IGF1 bioavailability and bioactivity.”
BackgroundSelf-citation
Cited by
Livingstone, C. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0231 · Cited by 296
Insulin resistance and cancer: The role of insulin and IGFs
Djiogue, S., Nwabo Kamdje, A. H., Vecchio, L., Kipanyula, M. J., Farahna, M., Aldebasi, Y., & Seke Etet, P. F. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0324 · Cited by 263
Insulin-Like Growth Factor 2 in Development and Disease: A Mini-Review
Bergman, D., Halje, M., Nordin, M., & Engström, W. (2013) · Gerontology · doi:10.1159/000343995 · Cited by 260
Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer
Kasprzak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126434 · Cited by 248
Insulin-like growth factor (IGF) axis in cancerogenesis
Kasprzak, A., Kwasniewski, W., Adamek, A., & Gozdzicka-Jozefiak, A. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.08.007 · Cited by 130
Zhang, W. B., Aleksic, S., Gao, T., Weiss, E. F., Demetriou, E., Verghese, J., Holtzer, R., Barzilai, N., & Milman, S. (2020) · Cells · doi:10.3390/cells9061368 · Cited by 64
Metadata
- Authors
- Gao, Y., Katki, H., Graubard, B., Pollak, M., Martin, M., Tao, Y., Schoen, R. E., Church, T., Hayes, R. B., Greene, M. H., & Berndt, S. I.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-11-02
- Volume
- 131
- Issue
- 2
- Pages
- E105-13
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2151646894
- Cited by
- 59
- References
- 1
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.